Uploaded September 2026 | Updated September 2026, 1 week ago
Dr Philippe Pouletty, the founder of Carvolix and CEO of Truffle Capital, joins Tom Burges Watson on The Riyal Deal shortly after Crown Prince Mohammed bin Salman's Paris visit to unpack two major Franco-Saudi healthcare deals. Pouletty discusses plans to build a state-of-the-art manufacturing facility in Riyadh for AI-driven robotics that treat heart valve disease and brain strokes, markets he values at $23 billion by 2030, plus a cardiologist exchange program and future plans in mRNA and biotech. He explains why Saudi Arabia, not the US or China, was the clear choice for long-term partnership.
Guest: Dr Philippe Pouletty, Founder of Carvolix and CEO of Truffle Capital
Dr Philippe Pouletty, the founder of Carvolix and CEO of Truffle Capital, joins Tom Burges Watson on The Riyal Deal shortly after Crown Prince Mohammed bin Salman's Paris visit to unpack two major Franco-Saudi healthcare deals. Pouletty discusses plans to build a state-of-the-art manufacturing facility in Riyadh for AI-driven robotics that treat heart valve disease and brain strokes, markets he values at $23 billion by 2030, plus a cardiologist exchange program and future plans in mRNA and biotech. He explains why Saudi Arabia, not the US or China, was the clear choice for long-term partnership.
Guest: Dr Philippe Pouletty, Founder of Carvolix and CEO of Truffle Capital
